# Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma

> **NCT01400672** · PHASE1 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 8 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma

## Interventions

- **BIOLOGICAL:** Tumor Lysate Vaccine
- **DRUG:** Imiquimod
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT01400672
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07-17
- **Primary completion:** 2016-03-07
- **Final completion:** 2018-10-08
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Treatment ineffective; Extreme toxicity
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01400672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01400672, "Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01400672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*